Gilead wins big reversal of patent verdict

Delaware federal judges overturned the jury's verdict and Gilead Science Inc. (Nasdaq: GILD) called for a record record of $ 254 million. Merck's patent (NYSE: MRK).

Merck said plans appeals in the statement and believes that the judge's judgment does not reflect facts of the incident. The ruling is the biggest ruling in the US patent litigation.

Wilmington, Del., February 23, 2018 / PRNewswire / - Fish & Richardson requested the client Gilead Sciences Inc a legal judgment (JMOL) in the Delaware state federal court. The $ 2.5 billion jury verdict was canceled. Judge Leonard P. Stark of the United States District Court on 16 February 2018 concluded Idenix Pharmaceutical '597 C hepatitis treatment patent is ineffective due to lack of treatment. This decision completely erased the jury's ruling against Gilead in December 2016. File and Merck and Idenix (now Merck) have represented Gilead for over five years in Gilead's worldwide complex patent fight between two heavy hepatitis C therapeutics, Sovaldi and Harvoni.

In December 2013, Idenix appealed Gi lead in Massachusetts State, claiming that Gilead infringed the Idenix '597 patent. In the trial, Fish considers the '597 patent to be invalid, as its explanation is inappropriate and does not explain the claimed invention nor implement so-called inventions. The jury sent a ruling to Gilead. After overturning the ruling, Fish 's trial team led by Frank Scherkenbach, Juanita Brooks, Jon Singer, Chad Shear, presented a lot of evidence on the problem of activation to Stark Judge. When JMOL was approved, Judge Stark discovered that without full-fledged experiments, this patent did not lead to the desire of general engineers.

Please consider some aspects. The first one is an invention: The team of Bennkeley's Jennifer Doudna applied for a patent seven months ago (No 13 / 842,859), but this decision is beneficial to Broad's Feng Zhang team. His patented Fast Track process (No. 14/054, 414) utilized the fact that the Patent Office was changed from "First Invention" to "First Application" on the second day after Doudna's submission . However, in a sense, these exercises are not important. Neither party invented Crispr technically, it just shows how to use the biological process as a tool. After all, the team of Zhang is thought to be the most clearly showing how Crispr is used in eukaryotic organisms - any organism composed of one or more complex cells.